Abstracts Archive - Page 15 of 2425 - ACR Meeting Abstracts

Abstract Number: 0193 • ACR Convergence 2024
New York City Lupus Clinical Trials Education Program
Maya Souvignier¹, Leila Khalili¹, Wai Yan April Fu², Laura Geraldino³, Nancyanne Schmidt¹, Yevgeniya Gartshteyn⁴, Peter Izmirly⁵, Noa Schwartz⁶ and Anca Askanase¹, ¹Columbia University Medical Center, New York, NY, ²Albert Einstein College of Medicine, New York, NY, ³Division of Rheumatology, Department of Medicine, Columbia University, New York, NY, ⁴Columbia University Irving School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY, ⁶Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY
Background/Purpose: Clinical trial (CT) participation is essential for the advancement of treatment paradigms and should be considered part of clinical care in SLE. CTs fail…
Abstract Number: 0029 • ACR Convergence 2024
Effect of Metformin on the Incidence of Total Knee Replacement: A Systematic Review and Meta-Analysis
Syed Hasan¹, Aali Furqan², Afia Salman³, hira Khan⁴, Sarah Aslam⁵, Alishba Rizvi⁴, Hafsah Alim Ur Rahman³, Muhammad Ahmed Ali Fahim³, Madiha Salman³, Eman Ali³, Yumna Furqan⁶, Shanta bai⁷, Farah Yasmin⁸ and Muhammad Sohaib Asghar⁹, ¹Dow University of Health Sciences, Karachi, PK., Karachi, Sindh, Pakistan, ²University of North Texas Health Science Center (UNT HSC), Texas, TX, ³Dow University of Health Sciences, Karachi, Pakistan, ⁴dow medical college, Karachi, Pakistan, ⁵Dow International Medical College, Karachi, Pakistan, ⁶Texas A&M School of Medicine, Dallas, TX, ⁷Liaquat National Hospital and Medical College, Karachi, Pakistan, ⁸Yale University School of Medicine, New Haven, CT 06511, U.S.A., New Haven, CT, ⁹AdventHealth, Sebring, FL
Background/Purpose: Osteoarthritis (OA) is among the most common debilitating conditions, causing disability and pain in older adults. For end-stage OA, total knee replacement (TKR) is…
Abstract Number: 0003 • ACR Convergence 2024
CLN-978, a CD19-directed T Cell Engager (TCE), Leads to Rapid and Deep B Cell Depletion and Has Broad Potential for Development in Autoimmune Diseases
Máire F. Quigley¹, Jennifer S. Michaelson¹, Jeffrey Jones¹, Farrukh T. Awan², Geoffrey P. Shouse³, Yue Zhang¹, Todd Shearer¹, Judy Inumerable¹, Irina M. Shapiro¹, Patrick A. Baeuerle¹ and Stephen Wax¹, ¹Cullinan Therapeutics, Inc., Cambridge, ²UT Southwestern Medical Center, Dallas, ³City of Hope Comprehensive Cancer Center, Duarte
Background/Purpose: CD19-directed CAR T cell therapy has been reported to induce profound B cell depletion and deep clinical responses, including drug-free remission, in patients with…
Abstract Number: 0007 • ACR Convergence 2024
Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation
Ryota Sato¹, Mitsuhiro Akiyama², Koichi Oshita³, Yuko Kawano³, Yuki Imura³, Piruzyan Mariam⁴, Manami Kikuchi³, Mikako Murase³, Sachiko Mochiduki³, Naohiro Hashimoto³, Masayuki Watanabe³, Keiko Yoshimoto⁵, Tsutomu Takeuchi⁶, Kenji Chiba⁷ and Yuko Kaneko⁵, ¹Mitsubishi Tanabe Pharma Corporation, Brighton, MA, ²Keio University School of Medicine, Palo Alto, CA, ³Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ⁴Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ⁵Keio University School of Medicine, Tokyo, Japan, ⁶Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁷Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
Background/Purpose: Proteins motifs bromodomain 1 (BD1) and BD2 within the BET family proteins regulate gene expression of inflammatory cytokines and lymphocyte proliferation by binding to…
Abstract Number: 0106 • ACR Convergence 2024
IgM and IgG Phosphatidylserine Antibody Detection May Improve Classification Accuracy of SLE and APS
Christina Donath¹, Sara Kahlown¹, Ryan Soares², Kamal Gautam², Mariam Saleh³, Banki Katalin⁴ and Andras Perl⁵, ¹SUNY Upstate University Hospital, Department of Medicine, Rheumatology Fellowship Program, Syracuse, NY, ²SUNY Upstate University Hospital, Department of Medicine, Internal Medicine Residency Program, Syracuse, NY, ³SUNY Upstate University Hospital, Syracuse, NY, ⁴SUNY Upstate University Hospital, Department of Pathology, Syracuse, NY, ⁵SUNY, Syracuse, NY
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune coagulopathy that causes microvascular and macrovascular thrombosis in both venous and arterial systems. This can occur as a…
Abstract Number: 0103 • ACR Convergence 2024
CD10highLow-Density Granulocytes Is a Potential Marker of Disease Activity in Antiphospholipid Syndrome
chun Li, Peking University People's Hospital, Beijing, China
Background/Purpose: To investigate the relationship between CD10highLow-Density Granulocytes (LDG) and disease activity in antiphospholipid syndrome(APS).Methods: This study included 99 patients with APS who were treated…
Abstract Number: 0010 • ACR Convergence 2024
Precision Editing of Cyclophilin a to Engineer Cyclosporine- and Voclosporin- Resistant Human CAR-T Cells
Holly Wobma¹, Francesca Alvarez-Calderon², Jiayi Dong², Alexandre Albanese², Kayleigh Omdahl², Rene Bermea³, Gillian Selig⁴, Marlana Winschel², Elisa Rojas Palato², Katherine Michaelis¹, Xianliang Rui², Bruce Blazar⁵, Susan Prockop², Victor Tkachev³, Ulrike Gerdemann² and Leslie Kean², ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, ³Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ⁴Harvard College, Boston, MA, ⁵Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, MN
Background/Purpose: With exponential demand for chimeric antigen receptor (CAR) therapies for autoimmune disease, allogeneic options will be essential. Advantages include use of healthy donor cells,…
Abstract Number: 0002 • ACR Convergence 2024
Preclinical Evaluation of BCMA And/or CD19 Nanobody-based Single or Compound CAR-T Cells Targeting B and Plasma Cells Associated with Autoimmune Disorders
Byeong Hyeok Choi¹, Vincent M DeStefano², Masayuki Wada², Kevin G Pinz¹, Greg Deener², Nabil Hagag¹, Ahmed Abdel-Razek¹, Yu Ma³, Jing Luo³ and Yupo Ma², ¹iCell Gene Therapeutics Inc., Stony Brook, NY, ²iCell Gene Therapeutics, Inc., Stony Brook, NY, ³iCar Bio Therapeutics Ltd, Zhongshan City, Guangdong, China (People's Republic)
Background/Purpose: CD19 single and BCMA-CD19 compound chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable activity against autoimmune disorders, although relapses with CD19 CAR…
Abstract Number: 0018 • ACR Convergence 2024
Preclinical Analysisof CB-010, an Allogeneic anti-CD19CAR-T Cell Therapywith a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
Elizabeth Garner, George Kwong, Tristan W Fowler, Heinrich Kufeldt, Brian Kerfs, Julie Kim, Art Aviles, Lynne Alexander, Franco Davi, Chris Holland, Jean-Yves Maziere, Ashraf Garrett, Mara Bryan, Linh Chu, Sarbani Bhaduri, Michele Gerber, Elaine Alambra, Justin Skoble, Tom Kochy, Tonia Nesheiwat, Socorro Portella, Enrique Zudaire and Steven B Kanner, Caribou Biosciences, Berkeley, CA
Background/Purpose: Autologous CD19-directed CAR-T cell therapy has been shown to eradicate aberrant B cells leading to durable clinical responses in SLE patients (Müller 2024; Wang 2024). However, autologous CAR-T cell…
Abstract Number: 0006 • ACR Convergence 2024
NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases
Mark Noviski¹, Jun Ma¹, Nivetha Brathaban¹, Aishwarya Kumar¹, Dhwani Haria¹, Jenny McKinnell¹, Robert Cass¹, Frederick Cohen¹, Davorka Messmer², Gwenn Hansen¹ and Ryan Rountree¹, ¹Nurix Therapeutics, San Francisco, CA, ²Nurix Therapeutics, San Diego, CA
Background/Purpose: Bruton’s tyrosine kinase (BTK) mediates signaling downstream of the B cell receptor (BCR), toll-like receptors (TLRs), and Fc receptors (FcRs). This makes BTK an…
Abstract Number: 0079 • ACR Convergence 2024
Characterization of the Tissue Resident Memorial T Cells in Autoimmune Arthritis: A Comparative Study of Psoriatic Arthritis and Rheumatoid Arthritis
Siba Raychaudhuri¹, Christine Abria² and Smriti K Raychaudhuri³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²VA Medical Center Sacramento, Mather, CA, ³VA Sacramento Medical Center, Mather, CA
Background/Purpose: Tissue-resident memory T cells (TRM) cells can drive localized, recurrent inflammation. TRM are site-specific T cells that take up long-term residence in peripheral tissues…
Abstract Number: 0082 • ACR Convergence 2024
Comparative Immunology of Entheseal Anchorage Sites Between Spine, Hip and Knee Demonstrates up to 70-fold Greater IL-23 Induction from Axial Enthesis Bone: A New Angle on the Failure of IL-23 Blockade in Ankylosing Spondylitis
Mark Harland¹, Paula David², Chi Wong¹, Jake Weddell¹, Abhay Rao³, Almas Khan³, Jake Timothy³, Peter Loughenbury³, Robert Dunsmuir³, Vishal Borse³, Campbell MacEachern³, Antonius Pieter Van der Heuvel⁴, Warner Chen⁴, Tom Macleod¹ and Dennis McGonagle⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK, Leeds, United Kingdom, ²Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel, Ramat Gan, Israel, ³Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, ⁴Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, USA, Spring House, PA, ⁵National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom
Background/Purpose: Both peripheral and axial spondyloarthropathy (SpA), psoriasis and inflammatory bowel disease are strongly linked to IL-23 pathway immunogenetics and immunology. Unexpectedly, IL-23 inhibition lacked…
Abstract Number: 0075 • ACR Convergence 2024
Micro-RNAs as Biomarkers for Methotrexate Treatment Response in Patients with Psoriatic Arthritis
Darshini Ganatra¹, Omar Cruz Correa¹, Ameth Garrido², Starlee Lively³, Rohan Apurva Machhar⁴, Remy Pollock⁵, Mohit Kapoor⁶ and Dafna Gladman⁷, ¹University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³UHN, Toronto, Canada, ⁴Novartis, Mississauga, ON, Canada, ⁵Pfizer, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a form of inflammatory arthritis linked to psoriasis, a chronic skin and nail disease. PsA is a progressive joint disease…
Abstract Number: 0072 • ACR Convergence 2024
The Association Between Activation of Inflammasome and HLA-B27 in Dendritic Cells of Patients with Axial Spondyloarthritis
Jina Yeo¹, Min-Gang Kim², Hye Eun Lee³, Yeonsoo Yang², Mi Ryoung Seo¹, Hyo-Jin Choi¹, Eun Young Lee⁴, Dae Ho Lee³ and Han Joo Baek⁵, ¹Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, ²Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea, ³Division of Endocrinology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, ⁴3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Inchon, South Africa
Background/Purpose: Axial spondyloarthritis (axSpA) exhibits a predominant involvement of the innate immune system, marked by abnormal functions of innate immune cell such as dendritic cells…
Abstract Number: 0020 • ACR Convergence 2024
CD14 Deficiency Protects Against TLR4/LPS-mediated Inhibition of Osteoclastogenesis
Lance Murphy¹, Kevin Burt², Vu Nguyen³, Baofeng Hu², Robert Mauck³ and Carla Scanzello², ¹University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia
Background/Purpose: Osteoarthritis is associated with bone changes such as subchondral sclerosis, bone marrow lesions, and osteophyte formation (Donel S, 2019). Prior work has demonstrated that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].